发布求助
文献互助 智能选刊 最新文献

Hepatology最新文献

筛选
英文 中文
Reply: The CRAPT-M score: Robust enough for clinical practice? 答复：crap - m评分：是否足以用于临床实践？
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-14 DOI: 10.1097/hep.0000000000001488
Heechul Nam,Jeong Won Jang
{"title":"Reply: The CRAPT-M score: Robust enough for clinical practice?","authors":"Heechul Nam,Jeong Won Jang","doi":"10.1097/hep.0000000000001488","DOIUrl":"https://doi.org/10.1097/hep.0000000000001488","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"181 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response. 致编辑的信：外周foxp3高Tregs作为HCC预后和免疫治疗反应的双重生物标志物。
IF 15.8 1区 医学
Hepatology Pub Date : 2025-08-13 DOI: 10.1097/HEP.0000000000001491
Chien-Hao Huang, Wei-Ting Ku, Wei Teng, Wen-Juei Jeng, Chun-Yen Lin
{"title":"Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response.","authors":"Chien-Hao Huang, Wei-Ting Ku, Wei Teng, Wen-Juei Jeng, Chun-Yen Lin","doi":"10.1097/HEP.0000000000001491","DOIUrl":"10.1097/HEP.0000000000001491","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details. 答复：新生肝门周围胆管癌的治疗方案需要更多的细节。
IF 15.8 1区 医学
Hepatology Pub Date : 2025-08-13 DOI: 10.1097/HEP.0000000000001497
Yawen Dong, Zhihao Li, Gregory J Gores, Julie K Heimbach, Rory L Smoot, Timucin Taner, Patrick P Starlinger
{"title":"Reply: The treatment options for de novo perihilar cholangiocarcinoma require more details.","authors":"Yawen Dong, Zhihao Li, Gregory J Gores, Julie K Heimbach, Rory L Smoot, Timucin Taner, Patrick P Starlinger","doi":"10.1097/HEP.0000000000001497","DOIUrl":"10.1097/HEP.0000000000001497","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: The treatment options for de novo perihilar cholangiocarcinoma require more details. 致编辑：新发肝门周围胆管癌的治疗方案需要更多的细节。
IF 15.8 1区 医学
Hepatology Pub Date : 2025-08-13 DOI: 10.1097/HEP.0000000000001496
Qin Zeng, Danna Xie, Qiao Zhou, Baolin Qian
{"title":"Letter to the Editor: The treatment options for de novo perihilar cholangiocarcinoma require more details.","authors":"Qin Zeng, Danna Xie, Qiao Zhou, Baolin Qian","doi":"10.1097/HEP.0000000000001496","DOIUrl":"10.1097/HEP.0000000000001496","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving? 甜菜碱治疗脂肪肝——历史潮流还是值得复兴的永恒宝藏？
IF 15.8 1区 医学
Hepatology Pub Date : 2025-08-13 DOI: 10.1097/HEP.0000000000001492
Manal F Abdelmalek, Keith D Lindor
{"title":"Betaine in the treatment of steatotic liver disease-Historical fad or a timeless treasure worth reviving?","authors":"Manal F Abdelmalek, Keith D Lindor","doi":"10.1097/HEP.0000000000001492","DOIUrl":"10.1097/HEP.0000000000001492","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":""},"PeriodicalIF":15.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: The CRAPT-M Score: Robust enough for clinical practice? 致编辑的信：crap - m评分：是否足以用于临床实践？
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-07 DOI: 10.1097/hep.0000000000001487
Xiaoping Zhu,Shenglong Li
{"title":"Letter to the Editor: The CRAPT-M Score: Robust enough for clinical practice?","authors":"Xiaoping Zhu,Shenglong Li","doi":"10.1097/hep.0000000000001487","DOIUrl":"https://doi.org/10.1097/hep.0000000000001487","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"17 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD. 回复：在探索MASLD儿童死亡率时应重新考虑血压调节和竞争风险分析。
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-04 DOI: 10.1097/hep.0000000000001486
Nhat Quang N Thai,Nidhi P Goyal,Kimberly P Newton,Jeffrey B Schwimmer
{"title":"Reply: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD.","authors":"Nhat Quang N Thai,Nidhi P Goyal,Kimberly P Newton,Jeffrey B Schwimmer","doi":"10.1097/hep.0000000000001486","DOIUrl":"https://doi.org/10.1097/hep.0000000000001486","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"28 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pilot trials of oral betaine in participants with non-alcoholic fatty liver disease and elevated alanine aminotransferase. 口服甜菜碱在非酒精性脂肪肝和谷丙转氨酶升高患者中的试点试验
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-04 DOI: 10.1097/hep.0000000000001477
Andrew S Lim,Sheena N Cruz,Aliya Asghar Uddin,Olga Malysheva,Marie A Caudill,Cristina Alonso,Alejandro Montilla,Morten A Karsdal,Diana Julie Leeming,Alejandro E Mayorca-Guiliani,Frederik Høbjerg Svejsø,Craig J McClain,Timothy R Morgan
{"title":"Pilot trials of oral betaine in participants with non-alcoholic fatty liver disease and elevated alanine aminotransferase.","authors":"Andrew S Lim,Sheena N Cruz,Aliya Asghar Uddin,Olga Malysheva,Marie A Caudill,Cristina Alonso,Alejandro Montilla,Morten A Karsdal,Diana Julie Leeming,Alejandro E Mayorca-Guiliani,Frederik Høbjerg Svejsø,Craig J McClain,Timothy R Morgan","doi":"10.1097/hep.0000000000001477","DOIUrl":"https://doi.org/10.1097/hep.0000000000001477","url":null,"abstract":"BACKGROUND/AIMBetaine, 20 grams/day for 12 months, reduced liver injury in several trials in non-alcoholic steatohepatitis (NASH). Our aim was to determine the safety and efficacy of lower doses of betaine in clinically diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) and an elevated ALT.METHODSWe performed three pilot trials in participants with clinically diagnosed non-cirrhotic MASLD and ALT ≥50 U/L. In the first trial, 44 participants were randomized to 4 g or 8 g daily for 12 weeks. In the second trial 10 participants received 1 g/d for 24 weeks while 16 participants received 2 g/d for 24 weeks in the third trial. Primary outcome was percent decline in abnormal component of ALT (ie, ALT >30 for males or >25 for females). Other outcomes included improvement in absolute ALT and AST, and other serologic tests of liver injury, including metabolomics-advanced steatohepatitis fibrosis (MASEF) score, cytokeratin 18, and pro-C3. Baseline and end of treatment data were compared with a paired t-test.RESULTSAt baseline, more than 75% of participants had NASH when tested by MASEF score. ALT, AST, cytokeratin 18, pro-C3, and MASEF score decreased significantly among participants receiving 8 g, 4 g, 2 g, but not 1 g. High density lipoprotein increased in the 4 g and 2 g cohorts; low density lipoprotein did not change. Approximately 35% reported mild, transient gastrointestinal symptoms.CONCLUSIONBetaine 8 g/d, 4 g/d, and 2 g/d for 12-24 weeks significantly reduced ALT and other serologic markers of liver injury among participants with clinically defined MASLD and an elevated ALT.","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"733 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis. 致编辑的信：真实世界的证据支持阿那白加锌治疗酒精相关性肝炎的肾毒性风险。
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-04 DOI: 10.1097/hep.0000000000001485
Peng Gao,Wukun Ge,Rongsong Wang
{"title":"Letter to the editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis.","authors":"Peng Gao,Wukun Ge,Rongsong Wang","doi":"10.1097/hep.0000000000001485","DOIUrl":"https://doi.org/10.1097/hep.0000000000001485","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"161 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD. 致编辑：在探索MASLD儿童死亡率时应重新考虑血压调节和竞争风险分析。
IF 13.5 1区 医学
Hepatology Pub Date : 2025-08-04 DOI: 10.1097/hep.0000000000001484
Yue Hu,Zheng Li,Xinran Cheng
{"title":"Letter to the editor: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD.","authors":"Yue Hu,Zheng Li,Xinran Cheng","doi":"10.1097/hep.0000000000001484","DOIUrl":"https://doi.org/10.1097/hep.0000000000001484","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":"26 1","pages":""},"PeriodicalIF":13.5,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144769707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信